Clinical Trials Browser

Withdrawn × INDUSTRY × daratumumab × Clear all

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT03221634 2019-03-25

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Phase 2 Withdrawn

Multiple Myeloma